PP-116 Comparison of HBV DNA results detected by 5 HBV/HCV/HIV-1 blood screening kits Introduction/Objectives: Chronic immunosuppression is a mainstay of treatment for rheumatologic diseases, but has been associated with hepatitis B reactivation. This review focused on the effectiveness of lamivudine as prophylaxis or treatment of hepatitis B reactivation among patients with rheumatologic diseases on chronic immunosuppression. Methods: A search of Medline, Pubmed and Cochrane databases was performed which yielded 18 studies including 4 observational cohort studies (1 prospective, 3 retrospective). Case reports and reviews were excluded. Authors were contacted to get fulltext articles.
Results: Forty-four rheumatologic patients on prednisolone alone or in combination with DMARDS or biologics, received lamivudine 100 mg/day as treatment (n = 22) for reactivation or as prophylaxis (n = 22). One study included 5 Lupus Nephritis patients while the 3 studies included patients with Rheumatoid Arthritis (n = 14), Systemic Lupus Erythematosus (n = 6), Ankylosing Spondylitis (n = 4), Polymyalgia Rheumatica (n = 5), Psoriatic Arthritis (n = 3) and 1 patient each with Systemic Sclerosis, Sjogren's Syndrome, Dermatomyositis/Polymyositis, Takayasu Arteritis, Henoch-Schonlein Purpura and Behcet's syndrome. Elevated levels of alanine transferase (ALT) at baseline (n = 22) normalized shortly after lamivudine therapy. HBV-DNA levels were significantly suppressed in 17 patients after treatment. Two patients developed treatment-resistant YMDD mutation of HBV and had to be shifted to adefovir. There were no major adverse events reported and lamivudine treatment appeared safe and well-tolerated. Conclusion: Lamivudine as treatment and prophylaxis for hepatitis B reactivation is a promising strategy in rheumatologic patients on chronic immunosuppression. However, the studies are limited by small sample sizes and heterogeneity, in terms of the type of rheumatologic disease, type and dosage of immunosuppressive drugs, and duration of lamivudine treatment. There is a need for further prospective, preferably RCTs including a larger set of patients.
PP-120 HBV contamination of medicine instruments in surgery department
M.M. Attarpour Yazdi 1 *. Results: The sex, age, BMI had no differennce in case and control group. Drinking of man in the CHB was higher than AHB, the virus-load was also higher in the group of CHB than AHB. A special serum construction: the masculine of HBsAg, HBeAg, anti-HBcIgG and PreSAg at the same time was the hight risk for CHB. But the high level of ALT, AST, TBIL was the low risk for CHB. IL-6 572GG genotype occurred more frequently in the CHB than that in the control (c 2 = 8.627, P = 0.003), with crude OR CG = 2.024, 95% CI: 1.009 4.06; OR GG = 3.367, 95% CI: 1.169 9.709. RANTES In1.1TC genotype occurred more frequently in the CHB than that in the controls (c 2 = 6.190, P = 0.018), with crude OR TC = 2.278, 95% CI: 1.079 4.808; OR TT = 1.845, 95% CI: 0.770 4.425. There were no interaction between the gene of IL-6 572 and the index which include ALT, HBeAg and virus load.
